The molecular mode of action of lonidamine, a therapeutic agent employed in cancer chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on mitochondria to induce apoptosis. LND provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis. The mitochondrial and cytocidal eects of LND are not prevented by inhibitors of caspases or of mRNA or protein synthesis. However, they are prevented by transfection-enforced overexpression of Bcl-2, an oncoprotein which inhibits apoptosis by stabilizing the mitochondrial membrane barrier function. Accordingly, the cell death-inducing eect of LND is ampli®ed by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective eect of Bcl-2. When added to isolated nuclei, LND fails to provoke DNA degradation unless mitochondria are added simultaneously. In isolated mitochondria, LND causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. Thus the mitochondrion is the subcellular target of LND. All eects of LND on isolated mitochondria are counteracted by cyclosporin A, an inhibitor of the mitochondrial PT pore. We therefore tested the eect of LND on the puri®ed PT pore reconstituted into liposomes. LND permeabilizes liposomal membranes containing the PT pore. This eect is prevented by addition of recombinant Bcl-2 protein but not by a mutant Bcl-2 protein that has lost its apoptosisinhibitory function. Altogether these data indicate that LND represents a novel type of anti-cancer agent which induces apoptosis via a direct eect on the mitochondrial PT pore.
Introduction
The chemotherapy of neoplasia aims at the induction of cancer cell death. In most cases, this cell death is mediated by apoptosis. As a result, the expression of apoptosis-regulatory gene products tends to be altered during the selection of chemotherapy-resistant cells. This applies to apoptosis-inhibitory proto-oncogene products such as Bcl-2, which are up-regulated, as well as to apoptosis-inducing anti-oncogenes such as p53 or Bax, which are down-regulated. Thus, these gene products contribute not only to the origins of cancer but also to the diculties in treating it (Jacobson et al., 1997; Thompson, 1995) .
According to present knowledge, apoptosis evolves in three functionally distinct phases: initiation, decision, and degradation. During the heterogeneous initiation phase, the sequence of biochemical events triggering apoptosis depends on the initiating stimulus. Dierent stimuli then converge on the common phase of apoptosis during which ®rst the`decision to die' is made and then, once beyond the point-of-no-return, the coordinate degradation of macromolecular structures ensues (Jacobson et al., 1997; Thompson, 1995) . Most of the data are compatible with the idea that the decisive event sealing the cell's fate is a disruption of mitochondrial membrane barrier function and that the activation of caspases and nucleases involved in apoptotic degradation critically relies on mitochondrial intermembrane proteins (cytochrome c, apoptosisinducing factor or AIF) that are released into the cytosol (Kluck et al., 1997; Liu et al., 1996; Susin et al., 1996; Yang et al., 1997; . One possible mechanism for the release of such mitochondrial intermembrane proteins is opening of the so-called mitochondrial megachannel or permeability transition (PT) pore, which is under the control of the members of the Bcl-2 family Marzo et al., 1998a,b; Pastorino et al., 1998; Zamzami et al., 1996; . This general model of cell death has been initially developed in receptor-mediated apoptosis and has been veri®ed in chemotherapyinduced cell death (Backway et al., 1997; Brunet et al., 1998; Decaudin et al., 1997; Fulda et al., 1998; Kim et al., 1997) .
Lonidamine (1-[(2,4-dichlorophenyl) methyl]-1H-indazole-3-carboxylic acid)] (LND) is a antineoplastic drug derived from indazole-3-carboxylic acid. In preclinical studies, LND has been shown to exacerbate the response of human tumor cells to cisplatin (Angioli et al., 1997; DeCesare et al., 1998; Pratesi et al., 1996) , irradiation (Dudak et al., 1996) , doxorubicin (Pratesi et al., 1996) , or cyclophosphamide (Pratesi et al., 1996) . LND is used in phase II and III trials of metastatic breast cancer (Dogliotti et al., 1998) and ovarian cancer (DeLena et al., 1997). Similar to other anticancer drugs, LND kills cells by inducing apoptosis (Del Bufalo et al., 1996) . Interestingly, LND appears to act on a dierent target than most other chemotherapeutic agents, since its eect is not in¯uenced by the p53 status (Del Bufalo et al., 1996) . Its apoptogenic eect is not fully understood, although LND has been suggested to: (a) act by interfering with the function of mitochondrion-bound hexokinase (Floridi et al., 1981; Oudard et al., 1995) ; (b) prevent aerobic glycolysis (Benhorin et al., 1995) ; (c) induce intracellular lactate accumulation leading to acidosis (Benhorin et al., 1995) ; (d) cause an increase in cytosolic Ca 2+ (Castiglione et al., 1993) and/or (e) interfere with respiration and maintenance of the mitochondrial transmembrane potential (Pulselli et al., 1996) .
Stimulated by these ®ndings, we decided to determine the mechanism of action of LND. We found that Bcl-2, which acts on mitochondrial membranes to inhibit opening of the PT pore Marzo et al., 1998b; Zamzami et al., 1996 Zamzami et al., , 1998a , is a potent inhibitor of LND-induced cell death. The analysis of the time course of LND-induced apoptosis and experiments performed with isolated organelles indicate that the subcellular target of LND is the mitochondrion. LND was found to have a direct eect on puri®ed PT pore complexes reconstituted into liposomes. Thus, it permeabilizes liposomes containing the PT pore complex in a Bcl-2-inhibitible fashion. These results indicate that LND has the unique property of inducing apoptosis via a direct eect on the PT pore complex.
Results and Discussion
LND induces mitochondrial alterations which precede nuclear apoptosis in vitro As shown in Figures 1 and 2 , treatment of cells with LND causes several hallmarks of apoptosis, including a dissipation of the mitochondrial transmembrane potential (DC m , measured by means of the potentiometric¯uorochrome DiOC 6 (3)), an increased generation of reactive oxygen species (ROS, measured by HE?Eth conversion), DNA fragmentation (measured as DNA loss causing a subdiploid phenotype of ethanol-®xed nuclei stained with the DNA intercalating dye PI) and a loss of cell viability (measured by means of the vital dye PI on un®xed cells). Kinetic analysis revealed that the DC m dissipation induced by LND precedes the nuclear changes (Figure 2e) , and for several doses of LND (200 ± 800 mM) the percentage of cells with a low DC m (DiOC 6 (3) low ) was higher than that of hypoploid cells (Figure 2a and c) . Similar results were obtained in dierent cell lines including U937 myelomonocytic cells (Figures 1 and 2 ), 2B4.11 T cell hybridoma cells, and CEM lymphoma cells (not shown), indicating that the early LND-triggered DC m dissipation is a general phenomenon.
Dierential inhibition of LND-induced apoptosis and cell death by Bcl-2 and Z-VAD.fmk
To dissect the mechanisms of LND-induced apoptosis, we evaluated the eect of inhibitors which frequently prevent apoptosis. Inhibition of mRNA or protein synthesis did not aect neither the LND-induced DC m reduction nor nuclear apoptosis, indicating that de novo synthesis of proteins is not required for LNDinduced apoptosis (Figure 3) . The caspase inhibitor Z-VAD.fmk prevented nuclear apoptosis induced by LND. However, it failed to prevent the LND-induced DC m reduction (Figure 3 ). This suggests that caspases are downstream eectors which are necessary for LND-triggered nuclear apoptosis but dispensable for LND-triggered mitochondrial changes. In contrast, overexpression of Bcl-2 prevented LND-induced DC m reduction, nuclear apoptosis, and cytolysis (Figures 1  and 2) . Surprisingly, Bcl-2 favored the generation of HE?Eth high cells, which remained DC m high (Figures 1a  and 2b ), a ®nding which is hitherto unexplained and which appears to be speci®c for LND because it is not observed with other apoptosis inducers such as tertbutylhydroperoxide, diamide or PK11195) (Hirsch et al., 1998; Zamzami et al., 1998b) . In any case, it appears that Bcl-2 but not Z-VAD.fmk prevents the DC m dissipation induced by LND.
PK11195 enhances the apoptogenic eect of LND and partially overcomes Bcl-2-mediated cytoprotection
We have previously shown that PK11195, an isoquinoline ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis by glucocorticoids, etoposide and irradiation (Hirsch et al., 1998) . Similarly, PK11195 potentiates the induction of apoptosis by LND. Whereas PK11195 alone does not induce any apoptosis-related changes, it greatly enhances the apoptogenic eect of LND (Figure 4) . Thus, doses of PK11195 or LND which themselves only have marginal eects on the DC m provoke a complete DC m loss when combined (Figure 4a ). An agonistic eect of PK11195 and LND was also found when nuclear apoptosis was measured (Figure 4b ). PK11195 partially overcomes the Bcl-2-mediated resistance to LND (Figure 4b ), a ®nding which underlines the role of mitochondria in determining apoptosis susceptibility. Moreover, this ®nding hints to the pro-apoptotic mode of action of molecules acting on the mitochondrial benzodiazepine receptor, one of which has been recently shown to act in vivo (Miccoli et al., 1998) .
LND requires mitochondria to induce apoptosis in a cell-free system
When added to isolated nuclei, the cytosol of LNDtreated cells induces nuclear apoptosis, as determined by measuring the DNA content by cyto¯uorometric analysis after staining with the DNA intercalating dye PI ( Figure 5 ). However, LND itself fails to induce nuclear apoptosis when added to puri®ed nuclei. In an attempt to determine which might be the intracellular target of LND, we added cytosols and puri®ed mitochondria to this cell-free system of apoptosis. Addition of cytosols without mitochondria did not reconstitute the LND response of isolated nuclei. LND only becomes eective in such a system in the presence of mitochondria. Thus, nuclei incubated with mitochondria undergo apoptosis, provided that LND is added to this mixture ( Figure 5 ). These results suggest that the apoptogenic eect of LND is mediated at least in part by mitochondria.
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LND causes opening of the mitochondrial PT pore in isolated mitochondria
When added to isolated mitochondria, LND causes a decrease in the mitochondrial transmembrane potential (Figure 6a ), as well as large amplitude swelling ( Figure  6b ). These eects are reminiscent of the opening of the PT pore, whose opening cause the dissipation of the mitochondrial transmembrane potential, as well as swelling of the mitochondrial matrix (Zoratti and SzaboÁ , 1995) . Accordingly, CsA, a prototype inhibitor of the PT pore (Connern and Halestrap, 1994; Petronilli et al., 1993; Zoratti and SzaboÁ , 1995) , prevents the LND-induced DC m fall and swelling. In most instances, Ca 2+ facilitates opening of the PT pore (Bernardi et al., 1992 SzaboÁ et al., 1992; Zoratti and SzaboÁ , 1995) . We therefore tested the eect of preloading of mitochondria with a low dose of Ca 2+ (5 mM), which on its own does not open the PT pore (Bernardi et al., 1992 SzaboÁ et al., 1992; Zoratti and SzaboÁ , 1995) . Ca 2+ pre-loading accelerates the LND-induced DC m dissipation and swelling (Figure 6a and b). Again, the combined eect of Ca 2+ and LND is completely inhibited by CsA (Figure 6a and b). The dose of LND required to induce CsA-inhibitible PT (50 mM in Figure 6 ) was lower than that required to induce loss of DC m in intact cells (ED50*200 mM in Figure 2 ). PT pore opening is known to cause the release of apoptogenic factors into the supernatant of mitochondria (Marchetti et al., 1996c; Petit et al., 1998; Susin et al., 1996; Zamzami et al., 1996) . Accordingly, the supernatants of mitochondria treated with LND but not those of control mitochondria contain cytochrome c (Figure 6d ), as well as factors capable of inducing apoptosis of isolated nuclei in vitro ( Figure  6c ). The release of these apoptogenic factors is inhibited by CsA. The notion that LND opens the CsA-inhibitable PT pore was con®rmed by continuous monitoring of mitochondria with a TPP + -sensitive electrode (for DC m quantitation) and oxymetry. Addition of LND causes a permanent reduction of the DC m and enhances oxygen consumption ( Figure  7a ), indicating uncoupling of the respiratory chain. None of these eects are detectable when mitochondria are pretreated with CsA ( Figure 7b ). Altogether, these ®ndings establish that LND can trigger opening of the mitochondrial PT pore, thereby releasing apoptogenic factors from the mitochondrion. or with human Bcl-2 were cultured during 6 h in the presence or absence (controls) of 800 mM LND, followed by staining with the DC m -sensitive dye DiOC 6(3) and HE, which is oxidized by ROS to the¯uorescent product ethidium (Eth). Numbers in each quadrant refer the percentage of cells. (b) LND eect on nuclear DNA content. Cells cultured as in a were permeabilized with ethanol and stained with the DNA intercalating dye PI, followed by determination of the frequency of subdiploid cells. (c) LND eect on cell viability. The permeability of the plasma membrane was determined by incubation of non-®xed cells with PI Direct LND eects on the puri®ed mitochondrial PT pore
The mitochondrial PT pore is a polyprotein structure which has recently been puri®ed and reconstituted into liposomes (Beutner et al., 1996; Marzo et al., 1998b) . Opening of the PT pore is responsible for the apoptotic DC m dissipation (Marchetti et al., 1996a; and can provoke the release of mitochondrial intermembrane proteins (Petit et al., 1998) . We therefore tested whether LND would open the PT pore reconstituted into liposomes. LND reduces the capacity of liposomes containing the PT pore to retain the¯uorochrome DiOC 6 (3) (Figure 8 ). In contrast, LND has no eect on liposomes that do not contain the PT pore (not shown). This suggests that the LND eect is mediated via the PT pore rather than by a non-speci®c membrane-destabilizing eect. To verify this hypothesis, we incorporated the PT pore into liposomal membranes in the presence of recombinant Bcl-2, which functions as a potent PT pore inhibitor Zamzami et al., 1998a) . As to be expected from the fact that Bcl-2 prevents LNDinduced apoptosis (Figures 1 and 2 ), Bcl-2 also inhibits the LND triggered opening of the PT pore in the reconstituted system. As a control, a mutant Bcl-2 protein that has lost its antiapoptotic function due to the deletion of a functionally important region (Da5/6) (Schendel et al., 1997) , fails to prevent LND-induced PT pore opening (Figure 8 ). These data are compatible with the hypothesis that LND induces apoptosis via a direct eect on the PT pore and that Bcl-2 antagonizes the LND eect via its PT pore-inhibitory function.
Concluding remarks
As shown in this paper, LND is likely to induce apoptosis by a direct eect on the mitochondrial PT pore complex. This interpretation is based on the observations that (a) LND induces early, caspaseindependent mitochondrial changes which closely correlate with later apoptosis and cytolysis ( Figures  1 ± 4) ; (b) LND requires mitochondria to induce nuclear apoptosis in a cell-free system ( Figure 5) ; (c) LND exerts direct, CsA-sensitive eects on isolated mitochondria (Figures 6 and 7) , leading to the release of apoptogenic factors (Figure 6c and d) and (d) LND has direct eects on the puri®ed mitochondrial PT pore complex in vitro (Figure 8 ).
To our knowledge, LND is the ®rst chemotherapeutic agent used in experimental cancer therapy that has a direct eect on the PT pore complex. We have previously described that the PT pore complex responds to a number of dierent molecules involved in pro-apoptotic signaling including reactive oxygen species, Ca 2+ , and Bax Zamzami et al., 1998a) . Moreover, the PT pore complex is a direct target of agents such as PK11195 (Hirsch et al., 1998) and the thiol-crosslinking agent diamide . Whereas these latter agents can overcome the apoptosis-inhibitory eect of Bcl-2 (Hirsch et al., 1998; Zamzami et al., 1998b) , the PT pore-opening eect of LND appears to be counteracted by Bcl-2, both in intact cells (Figures 1 and 2 ) and in puri®ed PT pore complexes (Figure 8 ). At present, the molecular mechanisms accounting for the dierential low and subdiploid cells eect of Bcl-2 are not fully understood. Bcl-2 does prevent opening of the PT pore in response to tertbutylhydroperoxide (Marzo et al., 1998a,b, Ca 2+ , atractyloside Susin et al., 1996; Zamzami et al., 1996) , and LND (this paper). However, it has no eect on PT pore opening induced by recombinant caspases-1 and 3 (which may digest Bcl-2 or Bcl-2-like proteins (Cheng et al., 1997) ), the thiol-crosslinking agent diamide , high doses of protoporphyrin IX (Marchetti et al., 1996b) , or a combination of atractyolside+PK11195 (Hirsch et al., 1998) or LND+PK11195 (this paper). We have recently found that the pro-apoptotic Bcl-2 homologue Bax physically interacts with the adenine nucleotide translocator (ANT) to induce PT pore opening . It is well possible that Bcl-2 prevents PT pore opening by a physical interaction with ANT . Our preliminary data indicate that diamide (and other thiol-crosslinking agents) directly aects the ANT, thereby abolishing the ANT-Bcl-2 interaction. This may explain how this type of agent can enforce PT pore opening in spite of the presence of Bcl-2. As to the mechanism of action of PK11195, we can only speculate. The mitochondrial benzodiazepine receptor, which is the putative target of PK11195, has been shown to interact with ANT (McEnery et al., 1992). Thus, it is possible that PK11195 indirectly aects the interaction between Bcl-2 and ANT.
LND has a variety of eects on cellular physiology which may be secondary to PT pore opening. Thus, LND causes an increase in cytosolic Ca 2+ levels (Castiglione et al., 1993) , and it is known that opening of the PT pore entails the mitochondrial release of Ca 2+ and increases cytosolic Ca 2+ levels . LND also disrupts aerobic glycolysis and reduces cellular ATP content (Benhorin et al., 1995; Fanciulli et al., 1996) . Again, these eects may well be secondary to opening of the PT pore with consequent uncoupling of the respiratory chain (Zoratti and SzaboÁ , 1995) . Finally, the activation of catabolic enzymes (nucleases and caspases) resulting into the acquisition of the apoptotic morphology is likely to rely on the mitochondrial release of proteins that are normally sequestered in them. Thus induction of PT is sucient to cause the release of intermembrane proteins such as cytochrome c (Kantrow and Piantadosi, 1997; Petit et al., 1998) , AIF Zamzami et al., 1996) , and caspases accumulating in the mitochondrion (Mancini et al., 1998) , which can then participate in the apoptotic degradation phase. In conclusion, it appears plausible that induction of PT accounts for the cytotoxic eects of LND.
The PT pore is a multiprotein complex that contains proteins involved in normal intermediate metabolism (hexokinase 1, porin, ANT) as well as apoptosisregulatory proteins (Bag-1, Bax) Zamzami et al., 1998a) . At present, it is unknown whether LND aects one particular protein within this complex. LND susceptibility has been correlated with the level of mitochondrion-associated hexokinase activity in glioma cells (Oudard et al., 1995) . However, LND acts on rat liver mitochondria ( Figure 6 ) which have no or little mitochondria-bound hexokinase (Bustamante et al., 1981) and it remains possible that LND acts on other proteins within the PT pore complex and/or aects the higher-order-structure that forms the PT pore complex. These possibilities are currently under active investigation in our laboratories.
The response of cells to dierent anti-cancer agents is frequently determined by signal-transducing events upstream of mitochondria. This is true for genotoxic events requiring activation of the p53 pathway (Lane, 1992; Polyak et al., 1997) or a series of chemotherapeutic agents involving signaling through the ceramide pathway Kolesnick and Kronke, 1998; Testi, 1996) , through changes in cellular redox potentials (Polyak et al., 1997) , or activation of the Fas/FasL system (Fulda et al., 1997; Herr et al., 1997) or analogous death receptors. Such agents thus elicit the generation of secondary messengers (p53-induced genes, ceramide, caspase-8 activation through Fas, etc.) which then aect mitochondria and induce cell death (Fulda et al., 1997; Herr et al., 1997; Kolesnick and Kronke, 1998; Lane, 1992; Polyak et al., 1997; Testi, 1996) . On theoretical grounds, agents which directly aect mitochondria and thus act on a more downstream level of apoptosis control, may be advantageous for treating cancers in which such signal-transducing systems are interrupted, e.g. due to mutations of p53 or due to the expression of endogenous inhibitors of the Fas pathway. Thus, LND and similar agents should have a broad cytotoxic potential with a reduced risk of developing drug resistance at the pre-mitochondrial level. As shown here, overexpression of the apoptosis inhibitor Bcl-2, which mainly acts on the mitochondrial level , confers resistance to LND. One strategy to overcome Bcl-2 mediated drug resistance may reside in the use of molecules such as PK11195, a ligand of the mitochondrial benzodiazepine receptor, which eectively sensitizes Bcl-2 overexpressing cells to the cytotoxic eect of several chemotherapeutic agents (Hirsch et al., 1998) including LND (Figure 4) .
Irrespective of these theoretical considerations, the data presented in this work suggest that LND is the prototype of a novel class of clinically used chemotherapeutic agents having a direct eect on the mitochondrial PT pore complex.
Figure 5 LND-induced nuclear apoptosis critically relies on mitochondria in a cell-free system. Puri®ed HeLa nuclei (1610 3 /ml) which were incubated (378C) during 30 min in CFS buer alone (Co.), in the presence of cytosol from U937 cells (®nal concentration 200 mg/ml), or with puri®ed mitochondria (®nal concentration 0.5 mg/ml), in the absence or presence of 50 mM LND. Note that LND has an apoptogenic eect only when added in the presence of mitochondria
Materials and methods
Induction, inhibition, and determination of apoptosis U937 cells transfected with a SFFV.neo vector containing the human bcl-2 gene or the neomycin resistance gene (Neo) only (Haener et al., 1999) or U937 wild type cells were cultured in RPMI 1640 medium supplemented with 10% FCS, Lglutamine, HEPES and antibiotics. Cells (1 ± 5610 5 ml 71 ) were cultured with variable doses of LND (Angelini Research Institute, Rome, Italy), 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK11105; Sigma, St. Louis, MO, USA), the caspase inhibitor N-benzyloxycarbonyl -Val -Ala -Asp.¯uoromethylketone ( Z -VAD .fmk ; 50 mM), cycloheximide (35 mM) and/or actinomycin D (1 mM). The LND stock solution (100 mM) was prepared in Nmethyl-D-glucamine (Fluca, Buchs, Switzerland) and diluted in complete culture medium. Control experiments revealed that N-methyl-D-glucamine (up to 1%) did not aect any apoptotic parameter (not shown). Following published protocols Marchetti et al., 1996a; Zamzami et al., 1995) , the following¯uorochromes were employed to determine dierent apoptosis-associated changes: 3,3'dihexyloxacarbocyanine iodide (DiOC (6)3 , 20 nM) for DC m quanti®cation; hydroethidine (HE, 4 mM) for the determination of superoxide anion generation; propidium iodide (PI, 5 mM) for the determination of viability. The frequency of subdiploid cells was determined by propidium iodide (PI) staining of ethanol-permeabilized cells . Cells were analysed in an Epics cyto¯uorometer (Coulter, Miami, FL, USA).
Assessment of mitochondrial parameters in vitro
Mitochondria were puri®ed from rat liver, as described (Costantini et al., 1996) , and resuspended in 250 mM sucrose+0.1 mM EGTA+10 mM N-tris[hydroxymethyl] methyl-2-Aminoethanesulfonic acid, pH=7.4). For the induction of PT, mitochondria (0.5 mg protein ml
71
) were resuspended in PT buer (200 mM sucrose, 10 mM Tris-MOPS (pH 7.4), 5 mM Tris-succinate, 1 mM Tris-phosphate, 2 mM rotenone, and 10 mM EGTA-Tris), and monitored in an F4500¯uorescence spectrometer (Hitachi, Tokyo, Japan) for the 908 light scattering (545 nm) to determine large amplitude swelling after addition of 2 mM actractyloside (Atr), 1 mM cyclosporin A (CsA; Novartis, Basel, Switzerland), 5 mM CaCl 2 , and/or 50 mM LND. For the determination of the DC m , mitochondria (0.5 mg protein per ml) were incubated in a buer supplemented with 1 mM rhodamine 123 (Molecular Probes, Eugene, OR, USA) and the dequenching of rhodamine¯uorescence (excitation 505 nm, emission 525 nm) was measured as described (Shimizu et al., 1998) . Supernatants from mitochondria (6800 g for 15 min; then 20 000 g for 1 h; 48C) were frozen at 7808C until determination of AIF activity or immunodetection of cytochrome c. Cytochrome c was detected by means of a monoclonal antibody (clone 7H8.2C12, Pharmingen). Membrane potential and oxygen uptake were simultaneously measured in an oxygen-electrode chamber (Hansatech Ltd., UK) using tetraphenylphosphonium cation (TPP + ) as a membrane potential probe. The transmembrane potential (DC m ) was measured at 258C in a ®nal volume of 1.5 ml respiratory medium consisting of 0.3 M sucrose, 10 mM KCl, 5 mM MgCl 2 , 10 mM TES, 10 mM KH 2 PO 4 (pH 7.2) (Petit et al., 1998) .
Cell-free system of apoptosis AIF activity in the supernatant of mitochondria was tested on HeLa cell nuclei, as described (Susin et al., 1997b) . Brie¯y, AIF-containing supernatants of mitochondria were added to puri®ed HeLa nuclei (90 min, 378C), which were stained with propidium iodide (PI) and analysed in an Elite II cyto¯uoremeter (Coulter) to determine the frequency of hypoploid nuclei. In some experiments isolated mitochondria, cytosols from U937 cells (prepared as described by Susin et al., 1997a) , and/or LND were added to the nuclei.
Puri®cation and reconstitution of PTPC in liposomes
PTPC from Wistar rat brain were puri®ed and reconstituted in liposomes following published protocols (Brenner et al., 1998; Marzo et al., 1998b) . Brie¯y, homogenized brains were subjected to the extraction of triton-soluble proteins, adsorportion of proteins to a DE52 resin anion exchange column, elution on a KCl gradient, and incorporation of fractions with maximum hexokinase activity into phosphatidylcholine/cholesterol (5 : 1, w/w) vesicles by overnight dialysis. Recombinant human Bcl-2 (1 ± 218) or mutant Bcl2Da5/6 (Bcl-2 (D143 ± 184), both lacking the hydrophobic transmembrane domain (D219 ± 239), produced and puri®ed as described (Schendel et al., 1997) ) were added during the dialysis step at a dose corresponding to 5% of the total PTPC proteins (approximately 10 ng Bcl-2 mg 71 lipids). Liposomes recovered from dialysis were ultrasonicated (120 W) during 7 s in 5 mM malate and 10 mM KCl, charged on a Sephadex G50 columns (Pharmacia), and eluted with 125 mM sucrose+10 mM HEPES (pH 7.4). Aliquots (approx. 10 7 ) of liposomes were incubated during 60 min at RT in 125 mM sucrose+10 mM HEPES (pH 7.4) in the presence or absence of LND or atractyloside. Then, liposomes were equilibrated with 3,3'dihexylocarbocyanine iodide (DiOC 6(3) , 80 nM, 20 ± 30 min at RT; Molecular Probes), and analysed in a FACS-Vantage cyto¯uoremeter (Becton Dickinson, San JoseÂ , CA, USA) for DiOC 6(3) retention, as described (Brenner et al., 1998; Marzo et al., 1998b) . Triplicates of 5610 4 liposomes were analysed and results were expressed as per cent of reduction of DiOC 6(3) uorescence, considering the reduction obtained with 0.25% SDS (15 min, RT) in PTPC liposomes as 100% value.
Figure 7 LND induces signs of PT in isolated mitochondria monitored constantly for oxygen consumption (line starting at top) and DC m (line starting at bottom). Simultaneous recording of oxygen consumption and of DC m was achieved with a Clark electrode and a TPP + electrode, respectively. Successive addition of Ca 2+ (50 nmol/mg mitochondrial protein) and LND (1.66 mM) was performed as indicated by arrows. This experiment was performed on control mitochondria (a) or on mitochondria pretreated with CsA (1 mM, 5 min) (b). Numbers refer to the oxygen consumption (nmol O 2 /min/mg protein) at the end of the experiment, after addition of LND Figure 8 LND causes PT pore opening in a Bcl-2-inhibitible fashion. PT pore complexes were puri®ed and reconstituted either alone or in the presence of recombinant Bcl-2 protein (or an inactive Bcl-2 mutant protein, Da5/6) into liposomes, as described in Materials and methods. After exposure to 100 mM LND, the liposomes were examined for the retention of the¯uorochrome DiOC 6(3) to assess their membrane permeability. SDS served as a positive control of permeabilization and Atr (100 mM) as an internal control of Bcl-2-inhibitable PT pore opening. Note that LND causes the permeabilization of PTPC liposomes and that this eect is inhibited by Bcl-2 but not by the Bcl-2Da5/6 control protein. Typical results out of three are shown
